Catalyst Wire Dossier Catalyst Wire Dossier

BYLVAY

odevixibat · Ipsen Biopharmaceuticals, Inc.
Drug timelines are a Plus or Pro feature.

8 regulatory and trial events tracked for BYLVAY, covering 2021-07-20 to 2026-04-01. Get the full timeline:

Most recent: Clinical Trial Update: A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment

See pricing